X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/sentynl-therapeutics-announces-global-acquisition-of-zokinvy-lonafarnib-for-treatment-of-hutchinson-gilford-progeria-syndrome-from-eiger-biopharmaceuticals-302135968.html
https://www.biospace.com/article/eiger-files-for-bankruptcy-plans-to-shutter-operations-after-difficult-year/
https://www.globenewswire.com/news-release/2024/04/01/2855277/0/en/Eiger-BioPharmaceuticals-Files-for-Voluntary-Chapter-11-Protection.html
https://www.prnewswire.com/news-releases/eiger-and-partner-anges-receive-approval-for-zokinvy-lonafarnib-for-hutchinson--gilford-progeria-syndrome-and-processing-deficient-progeroid-laminopathies-in-japan-302038919.html
https://www.ema.europa.eu/en/documents/overview/zokinvy-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-to-discuss-phase-3-d-livr-study-results-of-lonafarnib-based-treatments-in-hepatitis-delta-virus-hdv-on-thursday-december-8-2022-301697555.html
https://www.pharmaceutical-technology.com/news/anges-eiger-zokinvy-japan/
https://www.clinicaltrialsarena.com/news/eiger-enrolment-phase-iii-hdv/
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-receives-rare-impact-award-for-innovation-from-the-national-organization-of-rare-disorders-nord-for-the-development-and-fda-approval-of-zokinvy-lonafarnib-301321817.html
https://www.fiercepharma.com/pharma/ultrarare-disease-drug-ascends-to-top-most-expensive-pharmacy-drugs-u-s-2021
https://www.fiercepharma.com/pharma/fda-approves-first-drug-zokinvy-by-eiger-for-rare-rapid-aging-disease
https://www.europeanpharmaceuticalreview.com/news/134330/fda-approves-first-treatment-for-rare-paediatric-genetic-diseases/
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-sells-priority-review-voucher-for-95-million-301178619.html
https://www.fiercepharma.com/pharma/fda-approves-first-drug-zokinvy-by-eiger-for-rare-rapid-aging-disease
https://www.prnewswire.com/news-releases/eiger-announces-positive-peginterferon-lambda--lonafarnib-combination-end-of-study-results-from-phase-2-lift-hdv-study-in-late-breaker-session-at-the-liver-meeting-digital-experience-2020-301174515.html
https://www.prnewswire.com/news-releases/eiger-announces-abstracts-highlighting-peginterferon-lambda-and-lonafarnib-in-chronic-hepatitis-delta-virus-hdv-infection-accepted-for-presentation-at-the-liver-meeting-digital-experience-2020-301165267.html
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-fda-acceptance-of-nda-for-filing-with-priority-review-of-zokinvy-lonafarnib-for-treatment-of-progeria-and-progeroid-laminopathies-301062068.html
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-ema-validation-of-lonafarnib-maa-for-treatment-of-progeria-and-progeroid-laminopathies-301047377.html
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-ema-validation-of-lonafarnib-maa-for-treatment-of-progeria-and-progeroid-laminopathies-301047377.html
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-completes-submission-of-new-drug-application-to-fda-for-lonafarnib-for-treatment-of-progeria-and-progeroid-laminopathies-301027939.html
https://www.prnewswire.com/news-releases/eiger-announces-peginterferon-lambda---lonafarnib-combination-interim-results-in-hepatitis-delta-virus-hdv-infection-from-phase-2-lift-study-during-late-breaker-oral-presentation-at-aasld-2019-300956245.html
https://www.prnewswire.com/news-releases/eiger-announces-breakthrough-therapy-designation-granted-by-fda-for-avexitide-for-treatment-of-post-bariatric-hypoglycemia-pbh-300869814.html
https://www.biospectrumasia.com/news/25/12763/eiger-biopharma-gets-patent-protection-for-hdv-drug-in-europe-and-japan.html
https://www.biocentury.com/bc-extra/company-news/2018-09-04/eiger-seek-fda-approval-progeria-therapy
Market Place
Share 
